3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
26
Lymphoma, Non-Hodgkin
23
Lymphoma
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
19
Leukemia, Lymphocytic, Chronic, B-Cell
19
Myelodysplastic Syndromes
18
Hematologic Neoplasms
18
Melanoma
16
Neoplasm Metastasis
15
Lymphoma, B-Cell
14
Multiple Myeloma
12
Pancreatic Neoplasms
11
Hodgkin Disease
11
Stomach Neoplasms
10
Ovarian Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Breast Neoplasms
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Uterine Cervical Neoplasms
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Neoplasms, Plasma Cell
5
Kidney Neoplasms
5
Burkitt Lymphoma
5
Myeloproliferative Disorders
4
Interventions
Cyclophosphamide
2
sargramostim
1
iberdomide
1
fludarabine
1
dinutuximab
1
Topotecan
1
Magnetic Resonance Spectroscopy
1
Influenza Vaccines
1
Colony-Stimulating Factors
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ganglioneuroblastoma
×
fludarabine
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled